Fedratinib, a newly approved treatment for patients with ...
The JAKARTA trial evaluated fedratinib's efficacy and safety in JAK-inhibitor-naïve MF patients, showing significant spleen volume and symptom response improvements over placebo. JAKARTA2 assessed fedratinib in ruxolitinib-treated patients, demonstrating clinical activity with notable spleen volume and symptom response rates, supporting its use in MF treatment.
Reference News
Fedratinib, a newly approved treatment for patients with ...
The JAKARTA trial evaluated fedratinib's efficacy and safety in JAK-inhibitor-naïve MF patients, showing significant spleen volume and symptom response improvements over placebo. JAKARTA2 assessed fedratinib in ruxolitinib-treated patients, demonstrating clinical activity with notable spleen volume and symptom response rates, supporting its use in MF treatment.